

# ELEKTROTECHNICKÝ ZKUŠEBNÍ ÚSTAV



ELECTROTECHNICAL TESTING INSTITUTE - CZECH REPUBLIC  
ELEKTROTECHNISCHE PRÜFANSTALT - TSCHHECHISCHE REPUBLIK  
INSTITUT ELECTROTECHNIQUE D'ESSAIS - RÉPUBLIQUE TCHÉQUE  
ЭЛЕКТРОТЕХНИЧЕСКИЙ ИСПЫТАТЕЛЬНЫЙ ИНСТИТУТ - ЧЕШСКАЯ РЕСПУБЛИКА

Pod litem 129/2, 171 02 Praha 8 - Troja

## EC CERTIFICATE FULL QUALITY ASSURANCE SYSTEM

issued in accordance with Annex 2 of Government Order No. 54/2015 Coll.  
(Annex II of Directive 93/42/EEC)

No.: MED 200020

The Electrotechnical Testing Institute, Notified Body No. 1014, on the basis of the carried out audit results has decided that the quality system established at the

manufacturer

**DEFLAMED INTERNATIONAL s.r.o.**  
**Heřmanova 597/61, 170 00 Praha - Holešovice, Czech Republic**

for design, manufacturing and final inspection of medical device(s)

**DeflaGyn® vaginal gel - class IIa**

meets the provisions of Annex 2 of Government Order No. 54/2015 Coll., which specifies technical requirements for medical devices (Annex II of Directive 93/42/EEC). The certificate does not cover examination of the medical device design in accordance with Annex 2 clause 8 of Government Order No. 54/2015 Coll. (Annex II clause 4 of Directive 93/42/EEC).

The notified body agrees with attaching its identification number 1014 to CE marking, which will be affixed to the above mentioned medical device(s) in accordance with Article 6 of Government Order No. 54/2015 Coll. (clause 17 of Directive 93/42/EEC).

The decision was based on the results presented in the audit report No. **MED000078-02/01 of: 23.10.2019,**

**MED000078-03/01 of: 23.04.2020.**

The approved quality system established at the manufacturer is subject to regular surveillance audits by the notified body in accordance with Annex 2 clause 11 of Government Order No. 54/2015 Coll. (Annex II clause 5 of Directive 93/42/EEC). The manufacturer must inform the notified body which approved the quality system about any intention of substantial changes to the quality system or the product range covered. In case that the conditions under which the certificate has been issued are violated, the notified body may suspend the validity of the certificate or cancel the certificate.

For class III medical devices this certificate can be used only with EC Design-Examination Certificate issued in accordance with Annex 2 clause 8 of Government Order 54/2015 Coll. (Annex II clause 4 of Directive 93/42/EEC).

Edition 1

The first issue of this Certificate from 04.05.2020 with validity until 26.05.2024

**The validity of this Certificate is limited until: 26.05.2024**

04.05.2020

Prague

Mgr. Miroslav Sedláček  
Head of Certification Body



\* C E R / M E D 2 0 0 0 2 0 \*

MED000078-02

## Certificate history

Date	Status	Reason
04.05.2020	Issuance	Replacement of certificate No. MED 170055



*G. Klauč*

# DELFAMED International s.r.o.

Heřmanova 597/61  
170 00 Praha 7  
Czech Republic

Date: 2024-05-15

## Notified Body Confirmation Letter Reference: 1000178389

To whom it may concern,

### **Confirmation of the status of a formal application, written agreement, and appropriate surveillance in the framework of Regulation EU 2023/607 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for certain medical devices and in vitro diagnostic medical devices**

This letter confirms that, DQS Medizinprodukte GmbH, a Notified Body designated against Regulation (EU) 2017/745 (MDR) and identified by the number 0297 on NANDO, has received a formal application in accordance with Section 4.3, first subparagraph of Annex VII of MDR and has signed a written agreement in accordance with Section 4.3, second subparagraph of Annex VII of MDR with the following manufacturer:

## DELFAMED International s.r.o.

Heřmanova 597/61  
170 00 Praha 7  
Czech Republic

SRN:CZ-MF-000020041

The devices covered by the formal application and the written agreement mentioned above are identified in the Tables listed below: Table 1 identifies the devices for which an MDR application has been received, written agreement concluded and for which DQS Medizinprodukte GmbH is also responsible for appropriate surveillance of the corresponding devices under the applicable Directive. Table 2 identifies the devices for which an MDR application has been received and a written agreement concluded, but DQS Medizinprodukte GmbH has not yet taken the responsibility for appropriate surveillance of the corresponding devices under the applicable Directive.

In the case of devices covered by certificates issued under Directive 90/385/EEC (AIMDD) or Directive 93/42/EEC (MDD) that expired after 26 May 2021 and before 20 March 2023, without having been withdrawn, this letter also confirms that the manufacturer signed the written agreement under MDR by the date of MDD/AIMDD certificate expiry, or provided evidence that a competent authority of a Member State had granted a derogation or exemption from the applicable conformity assessment procedure in accordance with Article 59(1) of MDR or Article 97(1) of the MDR respectively, by the 20 Mar 2023 for the relevant devices. The transition timelines that apply to the devices covered by this letter, subject to the manufacturer's continued compliance to the other conditions specified in Article 120.3c of MDR (as amended by (EU) 2023/607), are shown below:

- 26 May 2026 for Class III custom-made implantable devices
- 31 December 2027 for Class III devices and Class IIb implantable devices excluding Well-established technologies (WET - sutures, staples, dental fillings, dental braces, tooth crowns, screws, wedges, plates, wires, pins, clips and connectors)
- 31 December 2028 for other Class IIb devices, Class IIa, Class I devices placed on the market in sterile condition or have a measuring function

- 31 December 2028 for devices not requiring the involvement of a notified body under MDD but requiring it under MDR (e.g., class I devices that qualify as re-usable surgical instruments)

On behalf of the Notified Body,



**Dr. Daniel Siuda**  
Regulatory Affairs Manager

**Table 1: Devices covered by this letter and for which the NB is also responsible for appropriate surveillance of the corresponding devices under the applicable Directive:**

Device name and Basic UDI-DI (as proposed by the manufacturer within the application)	MDR Device classification (as proposed by the manufacturer and verified at the pre-application stage)	If the MDR device is a substitute device, identification of the corresponding MDD/AIMDD device	MDD/AIMDD Certificate Reference(s) of the devices under MDR application, and the NB Identification
DeflaGyn® VAGINALGEL  Basic UDI-DI: 85930850382DFG1502822A	Class IIb excluding Class IIb implantable non-WET	N/A	Certificate #: MED 200020 NB #: 1014

**Table 2: Devices covered by this letter and for which the NB is NOT responsible for appropriate surveillance of the corresponding devices under the applicable Directive:**

Device name and Basic UDI-DI (as proposed by the manufacturer within the application)	MDR Device classification (as proposed by the manufacturer and verified at the pre-application stage)	If the MDR device is a substitute device, identification of the corresponding MDD/AIMDD device	MDD/AIMDD Certificate Reference(s) of the devices under MDR application, and the NB Identification
N/A	N/A	N/A	N/A

**Confirmation Letter Revision History**

Date	NB internal reference traceable to each version of the letter	Action
2024-05-15	<b>1000178389</b>	Initial issue